Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Bile Duct Cancer Pipeline Drugs Market Report Overview

Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy.

The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer and features dormant and discontinued projects.

Bile Duct Cancer Pipeline Drugs Market Segmentation by Targets

Some of the targets in the Bile Duct Cancer pipeline are Programmed Cell Death 1 Ligand 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, and Fibroblast Growth Factor Receptor 1 among others. Programmed Cell Death 1 Ligand 1 was the largest target in the pipeline.

Bile Duct Cancer Pipeline Drugs Market Analysis, by Targets

Bile Duct Cancer Pipeline Drugs Market Analysis, by TargetsFor more Bile Duct Cancer pipeline drugs market target insights, download a free report sample

Bile Duct Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the mechanisms of action in the Bile Duct Cancer pipeline drugs market are Programmed Cell Death 1 Ligand 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor among others. Programmed Cell Death 1 Ligand 1 Inhibitor was the leading MoA in the pipeline.

Bile Duct Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action

Bile Duct Cancer Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more MoA insights into the Bile Duct Cancer pipeline drugs market, download a free report sample

Bile Duct Cancer Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Bile Duct Cancer pipeline drugs market are intravenous, oral, subcutaneous, and intravenous drip among others. The majority of the pipeline drugs followed the intravenous route of administration.

Bile Duct Cancer Pipeline Drugs Market Analysis, by Routes of Administration

Bile Duct Cancer Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Bile Duct Cancer pipeline drugs market, download a free report sample

Bile Duct Cancer Pipeline Drugs Market Segmentation by Molecule Types

The leading molecule types in the Bile Duct Cancer pipeline drugs market are small molecule, monoclonal antibody, gene-modified cell therapy, and monoclonal antibody conjugated among others. Small molecule was the leading molecule type in the pipeline.

Bile Duct Cancer Pipeline Drugs Market Analysis, by Molecule Types

Bile Duct Cancer Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the Bile Duct Cancer pipeline drugs market, download a free report sample

Bile Duct Cancer Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Bile Duct Cancer pipeline drugs market are AstraZeneca Plc, Bayer AG, Merck & Co Inc, and Advenchen Laboratories LLC among others. Among these, AstraZeneca Plc had the most number of products under development in 2022.

Bile Duct Cancer Pipeline Drugs Market Analysis by Key Companies

Bile Duct Cancer Pipeline Drugs Market Analysis by Key CompaniesTo know more about the Bile Duct Cancer pipeline drugs market companies, download a free report sample

Bile Duct Cancer Pipeline Drugs Market Report Overview

Key Targets Programmed Cell Death 1 Ligand 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, and Fibroblast Growth Factor Receptor 1
Key Mechanism of Actions Programmed Cell Death 1 Ligand 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, and Intravenous Drip
Key Molecule Types Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, and Monoclonal Antibody Conjugated
Key Companies AstraZeneca Plc, Bayer AG, Merck & Co Inc, and Advenchen Laboratories LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma).

  • The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Abbisko Therapeutics Co Ltd
AbbVie Inc
Ability Pharmaceuticals SL
ABL Bio Inc
ABM Therapeutics Inc
ADC Therapeutics SA
Advenchen Laboratories LLC
Affimed GmbH
Akeso Inc
Alaunos Therapeutics Inc
Alentis Therapeutics AG
Alkermes Plc
Alligator Bioscience AB
Alphamab Oncology
Alpine Immune Sciences Inc
Ambrx Biopharma Inc
Amgen Inc
AngioGenex Inc
Apexigen Inc
Apollomics Inc
Arbele Ltd
Ascelia Pharma AB
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Biostar Technologies Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co Ltd
BioMed Valley Discoveries Inc
BioNTech SE
Biosion Inc
Biotheus Inc
BJ Bioscience Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Celldex Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Chong Kun Dang Pharmaceutical Corporation
Corcept Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cyclacel Pharmaceuticals Inc
CytoImmune Therapeutics Inc
Daiichi Sankyo Co Ltd
Delcath Systems Inc
Delta-Fly Pharma Inc
Duo Oncology Inc
Eddingpharm Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Elucida Oncology Inc
EpimAb Biotherapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fujifilm Holdings Corp
Genenta Science SpA
Genentech USA Inc
GeneQuantum Healthcare Suzhou Co Ltd
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
Genome & Co
Genoscience Pharma
Genosco Inc
Gensun Biopharma Inc
GI Innovation Co Ltd
GO Therapeutics Inc
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
H3 Biomedicine Inc
Hangzhou Bensheng Pharmaceutical Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Heidelberg Pharma AG
Heilongjiang ZBD Pharmaceutical Co Ltd
Hutchison MediPharma Ltd
Ikena Oncology Inc
ImCare Biotech LLC
Immix BioPharma Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor Inc
Incyte Corp
Inmune Bio Inc
InnoCare Pharma Ltd
Innopharmax Inc
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Intensity Therapeutics Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kinnate Biopharma Inc
Komipharm International Co Ltd
KPC Pharmaceuticals Inc
LaNova Medicines Ltd
Leap Therapeutics Inc
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Ligand Pharmaceuticals Inc
LipoMedix Pharmaceutical Inc
Luzitin SA
MacroGenics Inc
MedAnnex Ltd
Medicenna Therapeutics Corp
MediciNova Inc
Medivir AB
Merck & Co Inc
Merck KGaA
Merus NV
Mina Therapeutics Ltd
Mirati Therapeutics Inc
Molecular Templates Inc
Nanjing KAEDI Biotech Inc
NanoCarrier Co Ltd
Nerviano Medical Sciences SRL
Netherlands Translational Research Center BV
NGM Biopharmaceuticals Inc
Nkarta Inc
Northwest Biotherapeutics Inc
Novartis AG
NuCana Plc
Nuvalent Inc
Orgenesis Inc
Otsuka Pharmaceutical Co Ltd
Perseus Proteomics Inc
Pfizer Inc
Pharma Mar SA
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Promontory Therapeutics Inc
Provecs Medical GmbH
Puma Biotechnology Inc
Puretech Health Plc
QED Therapeutics Inc
Quadriga BioSciences Inc
QureBio Ltd
Recordati SpA
RedHill Biopharma Ltd
Redx Pharma Plc
Relay Therapeutics Inc
RemeGen Co Ltd
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
Sanofi
Seagen Inc
Senhwa Biosciences Inc
Shandong Boan Biotechnology Co Ltd
Shandong Buchang Pharmaceutical Co Ltd
Shanghai Cell Therapy Group Co
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shouyao Holding Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sillajen Biotherapeutics
Sirnaomics Ltd
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
SupremeCure Pharma Inc
Suzhou Kebo Ruijun Biosciences Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Symphogen A/S
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
SyntheX Inc
Taiho Oncology Inc
Tango Therapeutics Inc
TCR2 Therapeutics Inc
Tempest Therapeutics Inc
Toray Industries Inc
Transcenta Holding Ltd
TransThera Sciences (Nanjing) Inc
TriSalus Life Sciences Inc
Tyra Biosciences Inc
VasGene Therapeutics Inc
Verismo Therapeutics
Virogin Biotech Ltd
Vivesto AB
WellMarker Bio Co Ltd
Xencor Inc
Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bile Duct Cancer (Cholangiocarcinoma) – Overview

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bile Duct Cancer (Cholangiocarcinoma) – Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) – Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) – Discontinued Products

Bile Duct Cancer (Cholangiocarcinoma) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects, 2022

Bile Duct Cancer (Cholangiocarcinoma) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.